

press release

## OTOFARMA: full exercise of the Greenshoe Option

*Naples, 2 September 2025* – **The Otofarma Group** – with over 30 years of experience in the hearing care sector and a leading manufacturer of hearing aids distributed mainly through the pharmaceutical channel – announces that, based on information provided by Alantra Capital Markets S.A.U., Italian Branch (hereinafter also referred to as 'Alantra'), as the entity responsible for stabilising the Company's ordinary shares (ISIN IT0005663361), Alantra has fully exercised the Greenshoe Option in the capital increase granted by the Company during the placement of its ordinary shares on the Euronext Growth Milan ('EGM') for a total of 190,500 shares, in order to cover the obligation to return the 190,500 shares related to the Over Allotment option granted by the shareholder Bartolomucci Holding S.r.l..

The exercise of the Greenshoe Option immediately terminates the stabilisation period, during which it is hereby disclosed that no stabilisation transactions have been carried out.

The reference price of the shares subject to the Greenshoe Option is €5.40 per share, corresponding to the price established in the context of the placement of the Company's shares, for a total value of €1,028,700, with payment expected by the 4th of September 2025.

Following the full exercise of the Greenshoe Option, the Offer involved a total of 1,947,000 ordinary shares of Otofarma in capital increase, including the shares resulting from the exercise of the greenshoe option by the Global Coordinator, for a total amount of €10,513,800.

Otofarma's share capital will therefore consist of 5,947,000 ordinary shares following the full exercise of the Greenshoe Option, and the free float calculated on the total number of ordinary shares will be equal to 32.74% of the share capital. This will be composed as follows:

Shareholder	Number of Shares	% of Share Capital	% of Voting Rights
<b>Bartolomucci Holding S.r.l.</b>	4,000,000	67.26%	67.26%
<b>Axon Partners Group SA</b>	592,800	9.97%	9.97%
<b>Invitalia S.p.A. (via Fondo Cresci al Sud)</b>	381,600	6.42%	6.42%
<b>Algebris Investments</b>	333,300	5.60%	5.60%
<b>Market</b>	639,300	10.75%	10.75%
<b>TOTAL</b>	<b>5,947,000</b>	<b>100%</b>	<b>100%</b>

For further information on the Greenshoe Option, please refer to the admission document available in the Investor Relations section of the website [www.otofarmaspa.com](http://www.otofarmaspa.com).

This press release is also issued on behalf of Alantra pursuant to Article 6(2) of Delegated Regulation (EU) 2016/1052.

The Company will publish the press release announcing the change in share capital following the filing of the completed share capital increase with the competent Companies Register in accordance with the law.

\*\*\*\*\*

The Company uses the EMARKET SDIR and STORAGE circuit, managed by Teleborsa, for the dissemination of Regulated Information. This system is authorized by [CONSOB](#) by resolutions No.

22517 and No. 22518 of November 23, 2022, pursuant to Article 113-ter, paragraph 4, letter a, of Legislative Decree No. 58/1998. For further information on the greenshoe option, please refer to the admission document available in the Investor Relations section of the website [www.otofarmaspa.com](http://www.otofarmaspa.com).

#### **Identification Codes**

Alphanumeric Code: OTO

ISIN for Ordinary Shares: IT0005663361

\*\*\*

#### **About Otofarma SpA**

Otofarma Group is a leader in the design, production, and distribution of customized hearing aids through pharmacies. Its reputation is built on technological innovation and continuous research, offering advanced audiological solutions at a guaranteed democratic price, with the goal of making hearing care more accessible and widespread.

Pioneering in telemedicine, Otofarma was the first company in Europe to introduce specialist tele-audiology services in pharmacies, today available under Otofarma brand in more 4,000 partner pharmacies, making access to diagnosis and personalized devices easier.

Founded by Gennaro Bartolomucci, now Chairman, and led by CEO Giovanna Incarnato Bartolomucci, the company holds six patents for its proprietary software and instruments. Its devices and services are distributed exclusively through partner pharmacies, ensuring a controlled, quality-focused business model.

#### **For more information:**

##### **Otofarma S.p.A. - Investor relations**

Anna Incarnato Bartolomucci

E-mail: [anna.incarnato@otofarma.it](mailto:anna.incarnato@otofarma.it)

mob: +39 347 0506780

##### **Alantra – Euronext Growth Advisor**

E-mail: [ega@alantra.com](mailto:ega@alantra.com)

mob: +39 334 6267242

##### **SEC Newgate – Media Relations**

+39 02 624 999 1

Michele Bon – [michele.bon@secnewgate.it](mailto:michele.bon@secnewgate.it) – +39 338 693 3868

Francesca Brambilla – [francesca.brambilla@secnewgate.it](mailto:francesca.brambilla@secnewgate.it) – +39 338 627 2146